Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-02-07
1998-05-05
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530331, A23J 120, A23C 2300, A23C 3500
Patent
active
057474591
ABSTRACT:
A method is provided for increasing and/or maintaining the level of intracellular glutathione. Pursuant to the invention, compositions including denatured and at least partially hydrolyzed proteins are administered to a patient in an amount sufficient to increase glutathione levels in the patient.
REFERENCES:
patent: 2712202 (1955-07-01), Hosler et al.
patent: 3737536 (1973-06-01), Sagner et al.
patent: 3755578 (1973-08-01), McFarland et al.
patent: 4001437 (1977-01-01), Jaeggi et al.
patent: 4016293 (1977-04-01), Coughlin
patent: 4175130 (1979-11-01), Yamanaka et al.
patent: 4335210 (1982-06-01), Meister et al.
patent: 4338315 (1982-07-01), Paget et al.
patent: 4398026 (1983-08-01), Takano et al.
patent: 4420479 (1983-12-01), Morwick et al.
patent: 4427658 (1984-01-01), Maubois et al.
patent: 4434158 (1984-02-01), Meister et al.
patent: 4438124 (1984-03-01), Meister et al.
patent: 4482574 (1984-11-01), Lee
patent: 4563471 (1986-01-01), Satzinger et al.
patent: 4636388 (1987-01-01), Lin et al.
patent: 4647453 (1987-03-01), Meisner
patent: 4647571 (1987-03-01), Meister et al.
patent: 4665082 (1987-05-01), Meister et al.
patent: 4710489 (1987-12-01), Meister
patent: 4752618 (1988-06-01), Mascioli et al.
patent: 4775675 (1988-10-01), Gyorgydeak et al.
patent: 4780475 (1988-10-01), Cerra et al.
patent: 4784685 (1988-11-01), Meister
patent: 4791125 (1988-12-01), Clark
patent: 4798835 (1989-01-01), Krupp et al.
patent: 4839387 (1989-06-01), Poli
patent: 4868114 (1989-09-01), Nagasawa et al.
patent: 4963577 (1990-10-01), Schorlemmer et al.
patent: 4981704 (1991-01-01), Thibault
patent: 5002953 (1991-03-01), Hindley
patent: 5028627 (1991-07-01), Kilbourn et al.
patent: 5039609 (1991-08-01), Klein
patent: 5053387 (1991-10-01), Alexander
patent: 5055446 (1991-10-01), Alexander et al.
patent: 5089268 (1992-02-01), Katz
patent: 5095027 (1992-03-01), Goldberg et al.
patent: 5158883 (1992-10-01), Griffith
patent: 5208249 (1993-05-01), Rowe et al.
Clintec Nutrition Company, Peptamen.RTM. Brochure (1987).
Clintec Nutrition Company, Peptamen.RTM. Brochure (1990).
Clintec Nutrition Company. Carnation.RTM. Peptamen.RTM. Liquid, Isotonic, Complete, Elemental Diet: Clinical Rationale (1987).
Clintec Nutrition Company, Evaluation of a Peptide-Based Elemental Diet versus an Amino Acid Based Elemental Diet in Geriatric Tube-Fed Patients (1987).
Clintec Nutrition Company, Carnation.RTM. Liquid Elemental Diet Flavoring Ideas (1988).
Clintec Nutrition Company, Use of PEPTAMEN.TM. Liquid, Isotonic, Complete, Elemental Diet in The Transition from TPN and Long-Term Management on Enteral Feeding (1987).
Clintec Nutrition Company, Use of PEPTAMEN.TM. Liquid, Isotonic, Complete, Elemental Diet in a Patient with a High-Output Ostomy (1987).
Clintec Nutrition Company, The Case for Peptides in a Defined Formula (1988).
Clintec Nutrition Company, The Case for a Balance-Energy-Substrate Formula (1988).
Feller et al, "Effects of Three Liquid Diets on Nutrition-Sensitive Plasma Proteins of Tube-Fed Elderly Men," J. of Am. Geriatrics Soc'y, No. 6, pp. 663-668 (1990).
Polk et al, "Intermittent Administration of a Defined Formula Diet Induces Growth in Adolescents With Crohn's Disease and Growth Failure," Pediatric Res. Abstract No. 664, 113A (1990).
Mandel, et al. Intracellular Glutathione in the Protection from Anoxic injury in Renal Proximal Tubles, J. Clin. Invest., 1990, vol. 85, No. 2, pp. 316-324. (Abstract).
Chang, et al., Cytoprotective Effect of Reduced Glutathione in Arsenical-Iduced Endothelial Cell injury, Toxicology, 1991, vol. 69, No. 1, pp. 101-110. (Abstract).
Moslen, Protection by L-2-Oxothiazolidine-4-Carboxylate, a Cysteine Prodrug, Against 1.1-Dichlorethylene Hepatotoxicity in Rats is Associated with Decreased in Toxin Metabolism and Cytochrome P-450, J. Pharmacol. Exp. Ther., vol. 248, No. 1, pp. 157-63. (Abstract).
Cretton, et al., Catabolism of 3'-Axido-3'Deoxythymidine in Hepactocytes and Liver Microsomes, with Evidence of Formation of 3'-Amino-3'-Deoxythmidine, a Highly Toxic Catabolite for Human Bone Marrow Cells, Molecular Pharmacology, vol. 39, pp. 258-266, 1991.
Handlon, et al. Thiol Reduction of 3'-Aziodthymidine to 3'-Aminothymidine: Kinetics and Biomedical Implications, Pharmaceutical Research, vol. 5, No. 5, pp. 297-299, 1988.
Lamperth, et al. Abnormal Skeletal and Cardiac Muscle Mitochondria Induced by Zidovudine (AZT) in Human Muscle in vitro and in an Animal Model, Laboratory Investigation, vol. 65, No. 6, pp. 742-752, 1991.
Bone, et al. Definitions for Sepsis and Organ Failure, Critical Care Medicine, 1992, vol. 20, No. 6, pp. 724-725.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis, Critical Care Medicine, Jun. 1992, vol. 20, No. 6, pp. 864-874.
Kilbourn et al., Inhibition of Interleukin-1-.alpha.-Induced nitric Oxide Synthase in Vascular Smooth Muscle and Full Reversal of Interleukin-1-.alpha. induced Hypotension by N.sup.107 -Amino-L=Argine, Journal of the National Cancer Institute, Jul. 1, 1992, vol. 84, No. 13, pp. 1008-1016.
Osol, et al. Eds., Reminington's Pharmaceutical Sciences, 1980, Sixteenth Edition.
W. Lucht et al., Prevention of Release of Granulocyte Aggregants into Sheep Lung Lymph Follownig Endotoxemia by N-Acetylcysteine, The American Journal of the Medical Sciences, vol. 294, No. 3, Sep. 1987, pp. 161-167.
G. Bernard et al., Effect of N-Acetylcysteine on the Pulmonary Response to Endotoxin in the Awake Sheep, and Upon In Vitro Granulocyte Function, J. Clin. Invest., vol. 73, Jun. 1984, pp. 1772-1784.
A. Cantin et al., Normal Alveolar Epithelial Lining Fluid Contains High Levels of Glutathione, pp. 152-157.
L. Smith et al. Effect of Fasting on Hyperoxic Lung Injury in Mice, Am. Rev. Respir. Dis. 1990; 141:141-149.
J. Strausz et al. Oxygen Radical Production bv Alveolar Inflammatory Cells in Idiopathic Pulmonary Fibrosis, Am. Rev. Respir. Dis. 1990; 141:124-128.
A. Cantin et al., Glutathione Deficiency in the Epithelial Lining Fluid of the Lower Respiratory Tract in Idiopathic Pulmonary Fibrosis, Am. Rev. Respir. Dis. 1989; 139:370-372.
A. Cantin et al., Oxidants. Antioxidants and the Pathogenesis of Emphysema, Eur. J. Respi. Dist (l985) 66, Suppl. 139. pp.7-17.
I. Cotgreave et al. Lung and Systemic Thiol Homeostasis During an Acute Lung Inflammation in the Rat, Toxicology, 50 (1988), pp. 331-343.
J. Sun et al. Effects of Buthionine Sulfoximine on the Development of Ozone-Induced Pulmonary Fibrosis, Experimental and Molecular Pathology 49 (1988), pp. 254-266.
S. Baldwin et al. Oxidant Activity in Expired Breath of Patients with Adult Respiratory Distress Syndrome, The Lancet, Jan. 4, 1986, pp. 11-14.
M.F. Tsan et al. Enhancement of Intracellular Glutathione Protects Endothelial Cells Against Oxidant Damage, Biochemical and Biophysical Research Communications, vol. 127, No. 1, Feb. 28, 1985, pp. 270-276.
M.F. Tsan et al. L-2-Oxothiazolidine-4-Carboxylate Protects Endothelial Cells Against Hperopia-Induced Injury, Inflammation, vol. 12, No. 2, 1988, pp. 113-121.
P.H.S. Sporn et al. Complex Effects of In Vitro Hyperoxia on Alveolar Macrophage Arachidonic Acid Metabolism, American Journal of Respiratory Cell and Molecular Biology, vol. 2, No. 1, Jan. 1990, pp. 81-90.
M.A. Passero et al., L-2-Oxothiazolidine-4-Carboxylic Acid Increases Glutathione in Mouse Lung, A. Rev. Respir. Dis. vol. 133, 1986, p. A395. (Abstract).
Uhlig, et al. Glutathione Enhancement in Various Mouse Organs and Protection by Glutathione Isopropyl Ester Against Liver Injury, Jun. 15, 1990, pp. 1877-1880.
Bellin, et al., Purification of Glycosaminoglycens from Bovine Follicular Fluid, J. Dairy Sci., No. 9, 1987, vol. 70, pp. 1913-1919.
Calvin, et al., Estimation and Manipulation of Glutathione Levels in Prepuberal Mouse Ovaries and Ova: Relevance to Sperm Nucleus Transformation in the Fertilized Egg, Gamete Research, 1986, vol. 14, pp. 265-275.
Gordon e
Madsen David C.
Mark David A.
Rowe W. Bruce
Nestec Ltd.
Touzeau Lynn
Tsang Cecilia J.
LandOfFree
Method for insuring adequate intracellular glutathione in tissue does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for insuring adequate intracellular glutathione in tissue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for insuring adequate intracellular glutathione in tissue will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-54595